Kyowa Kirin Group
Phone: +1 0352057200
Web: https://www.kyowakirin.com
| Type | Public (K.K) |
|---|---|
| Traded as | TYO: 4151 Nikkei 225 Component |
| Industry |
|
| Founded | July 1, 1949 |
| Headquarters | Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan |
| Key people | Nobuo Hanai, (CEO and President) |
| Products |
|
| Revenue | $ 3.548 billion USD (FY 2013)
 (¥ 340.61 billion JPY) (FY 2013) |
| Net income | $ 31.32 million USD (FY 2013)
(¥ 30.07 billion JPY) (FY 2013) |
| Number of employees | 7,532 (consolidated) (as of December 31, 2017) |
| Parent | Kirin Holdings Company, Limited |
| Subsidiaries | 47 (33 in Japan and 14 overseas countries) |
| Website | Official website |
The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world. The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
For detailed contact information visit location pages below.
Kyowa Kirin Group's locations around the world
North America
Oceania
Clinical Trials sponsored by Kyowa Kirin Group
-
Institut de Recherches Internationales ServierKyowa Kirin Co., Ltd.; ADIR, a Servier Group companyConcluídoLeucemia linfoblástica agudaJapão